Loading
A phase 2 trial of Cadonilimab, Gemcitabine, Leucovorin (folinic acid) and Oxaliplatin in pancreatic ductal adenocarcinoma, run by Akeso, now recruiting.
A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer is a phase 2 interventional study registered as NCT05859750 by Akeso, with 78 participants planned, started 2023-05-25 and due to reach its primary completion in 2025-06. Interventions recorded: AK104, Gemcitabine, Nab-Paclitaxel, Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate and Oxaliplatin + Irinotecan + 5-Fluorouracil/Leucovorin.
Shares Akeso, Bispecific antibodies, Gemcitabine, Metastatic pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Cadonilimab, Akeso, Bispecific antibodies, Immune checkpoint inhibitors and the tag pipeline.
Shares Leucovorin (folinic acid), Oxaliplatin, Gemcitabine, Metastatic pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Cadonilimab, Akeso, Bispecific antibodies, Immune checkpoint inhibitors and the tag pipeline.
Shares Akeso, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Gemcitabine, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Gemcitabine, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Gemcitabine, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.